Beam Therapeutics Enterprise value
What is the Enterprise value of Beam Therapeutics?
The Enterprise value of Beam Therapeutics Inc. is $2.24B
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on NASDAQ compared to Beam Therapeutics
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Companies with enterprise value similar to Beam Therapeutics
- Stepan Co has Enterprise value of $2.23B
- Biffa Plc has Enterprise value of $2.24B
- Minmetals Land has Enterprise value of $2.24B
- Morneau Shepell has Enterprise value of $2.24B
- Kajaria Ceramics has Enterprise value of $2.24B
- Polar Capital Technology Trust Plc has Enterprise value of $2.24B
- Beam Therapeutics has Enterprise value of $2.24B
- InnoCare Pharma has Enterprise value of $2.24B
- Global Blue AG has Enterprise value of $2.24B
- Consolidated Communications Inc has Enterprise value of $2.24B
- Brookfield Asset Management Re has Enterprise value of $2.24B
- Indivior PLC has Enterprise value of $2.25B
- Rail Vikas Nigam has Enterprise value of $2.25B